Names and pronunciation
(fin-ass′te-ride) Propecia, Proscar
Source page 563
Loading InternPractice…
Individual generic drug information
Extracted information for finasteride only.
(fin-ass′te-ride) Propecia, Proscar
Source page 563
Func. class.: Hormone, androgen inhibitor, hair stimulant
Source page 563
Chem. class.: 5-α-Reductase inhibitor
Source page 563
Do not confuse: finasteride/furosemide Proscar/Prograf/Provera
Source page 563
ACTION: Inhibits 5-α-reductase and reduction in DHT; DHT induces andro- genic effects by binding to androgen receptors in the cell nuclei of the pros- tate gland, liver, skin; prevents develop- ment of BHP
Source page 563
USES: Symptomatic benign prostatic hyperplasia (Proscar); male-pattern baldness (Propecia)
Source page 563
Extracted information for finasteride only.
CONTRAINDICATIONS: Preg- nancy, breastfeeding, children, women who are pregnant or who may become pregnant should not handle tabs, hypersensitivity Precautions: Large residual urinary vol- ume, severely diminished urinary flow, F hepatic function abnormalities
Source page 563
SIDE EFFECTS GU: Impotence, decreased libido, decreased volume of ejaculate, sexual dysfunction, gynecomastia INTEG: Rash MISC: Breast tenderness, secondary malignancy
Source page 563
INTERACTIONS Drug/Lab Test Decrease: PSA levels
Source page 563
Extracted information for finasteride only.
DOSAGE AND ROUTES BPH • Adult: PO 5 mg/day × 6-12 mo (Proscar) Male-pattern baldness • Adult: PO 1 mg/day for 3 mo or more for results (Propecia)
Source page 563
Available forms: Tabs (Propecia) 1 mg, (Proscar) 5 mg
Source page 563
Administer: • Without regard to meals • For a minimum of 6 mo; not all pa- tients will respond • Store <86° F (30° C); protect from light; keep container tightly closed
Source page 563
Extracted information for finasteride only.
Assess: • BPH: urinary patterns, residual urinary volume, severely diminished urinary flow • PSA levels and exclusion of prostate/ urinary cancer before initiating therapy and periodically thereafter; PSA levels may be altered by this product • Hepatic studies before treatment; ex- tensively metabolized in liver • Pregnancy/breastfeeding: not to be used in females; do not use in pregnancy/ breastfeeding
Source pages 563, 564
Evaluate: • Therapeutic response: increased uri- nary flow; decreased postvoiding drib- bling, frequency, nocturia; hair growth within 3-6 mo; regression of prostate size
Source page 564
CLINICAL CONSIDERATIONS
Source page 563
Patient and caregiver information: • That pregnant women or women who may become pregnant should not touch crushed tabs or come into contact with the semen of a patient taking this prod- uct; that product may adversely affect developing male fetus • That volume of ejaculate may be de- creased during treatment; that impotence and decreased libido may also occur and may continue after discontinuing treat- ment • That Propecia results may not occur for 3 mo • That Proscar results may not occur for 6-12 mo
Source page 564
Extracted information for finasteride only.
PHARMACOKINETICS Bioavailability 63%; readily absorbed from GI tract; protein binding 90%; metabolized in the liver; excreted in urine (metabolites) 39%, feces (57%); crosses blood-brain barrier; peak 1-2 hr; duration 24 hr
Source page 563
Filter the extracted dose blocks for this individual drug.
BPH
• Adult: PO 5 mg/day × 6-12 mo (Proscar) Male-pattern baldness
Candidate age grouping · source page 563
BPH
• Adult: PO 1 mg/day for 3 mo or more for results (Propecia)
Candidate age grouping · source page 563